Nasdaq · CIK 0001699382
PMVP PMV Pharmaceuticals, Inc.
Insider trading from SEC Form 4. Last filing 7 d ago.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
12
with a Form 4 at this company
Signals
Open-market buys and sells at PMV Pharmaceuticals, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 36Weak | Orbimed Advisors LLC owner sell | $900k 500,000 shares | -8% | - | |
| 52Moderate | Michael Carulli Chief Financial Officer sell | $30k 28,249 shares | -32% | - | |
| 46Moderate | Deepika Jalota Chief Development Officer sell | $35k 33,065 shares | -27% | - | |
| 47Moderate | David Henry Mack President and CEO sell | $62k 58,411 shares | -10% | - | |
| 40Moderate | Robert Ticktin General Counsel & COO sell | $25k 23,151 shares | -19% | - |
Transactions
The last 16 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 1, 2026 | Matthew Joseph Eckler director | AGrant or award Stock Option (right to buy)derivative | +84,000 | $0.00 | $0 | 84,000 | 7 d ago |
| Sep 10, 2025 | Orbimed Advisors LLC owner | SOpen-market sale Common Stockindirect: See Footnotes | -500,000 | $1.80 | $900k | 5,975,291 | Sep 12, 2025 |
| Jul 1, 2025 | Michael Carulli Chief Financial Officer | SOpen-market sale Common Stock | -28,249 | $1.06 | $30k | 60,146 | Jul 3, 2025 |
| Jul 1, 2025 | Deepika Jalota Chief Development Officer | SOpen-market sale Common Stock | -33,065 | $1.06 | $35k | 89,959 | Jul 3, 2025 |
| Jul 1, 2025 | David Henry Mack President and CEO | SOpen-market sale Common Stock | -58,411 | $1.06 | $62k | 536,133 | Jul 3, 2025 |
| Jul 1, 2025 | Robert Ticktin General Counsel & COO | SOpen-market sale Common Stock | -23,151 | $1.06 | $25k | 98,695 | Jul 3, 2025 |
| Jun 5, 2025 | Charles M Baum director | AGrant or award Stock Option (right to buy)derivative | +33,500 | $0.00 | $0 | 33,500 | Jun 9, 2025 |
| Jun 5, 2025 | Kirsten Flowers director | AGrant or award Stock Option (right to buy)derivative | +33,500 | $0.00 | $0 | 33,500 | Jun 9, 2025 |
| Jun 5, 2025 | Carol Giltner Gallagher director | AGrant or award Stock Option (right to buy)derivative | +33,500 | $0.00 | $0 | 33,500 | Jun 9, 2025 |
| Jun 5, 2025 | Richard A. Heyman director | AGrant or award Stock Option (right to buy)derivative | +33,500 | $0.00 | $0 | 33,500 | Jun 9, 2025 |
| Jun 5, 2025 | Arnold J Levine director | AGrant or award Stock Option (right to buy)derivative | +33,500 | $0.00 | $0 | 33,500 | Jun 9, 2025 |
| Jun 5, 2025 | Laurie Stelzer director | AGrant or award Stock Option (right to buy)derivative | +33,500 | $0.00 | $0 | 33,500 | Jun 9, 2025 |
| Jun 5, 2025 | Carol Giltner Gallagher director | GGift Stock Option (right to buy)derivative | -33,500 | $0.00 | $0 | 0 | Jun 9, 2025 |
| Jun 5, 2025 | Carol Giltner Gallagher director | GGift Stock Option (right to buy)derivativeindirect: See footnote | +33,500 | $0.00 | $0 | 33,500 | Jun 9, 2025 |
| Mar 3, 2025 | Michael Carulli Chief Financial Officer | AGrant or award Employee Stock Option (right to buy)derivative | +265,000 | $0.00 | $0 | 265,000 | Mar 5, 2025 |
| Mar 3, 2025 | Deepika Jalota Chief Development Officer | AGrant or award Employee Stock Option (right to buy)derivative | +300,000 | $0.00 | $0 | 300,000 | Mar 5, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Charles M Baumdirector
- Michael CarulliChief Financial Officer
- Matthew Joseph Ecklerdirector
- Kirsten Flowersdirector
- Carol Giltner Gallagherdirector
- Richard A. Heymandirector
- Deepika JalotaChief Development Officer
- Arnold J Levinedirector
- David Henry MackPresident and CEO
- Orbimed Advisors LLCdirector, owner
- Laurie Stelzerdirector
- Robert TicktinGeneral Counsel & COO
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.